- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06352684
Effectiveness of CadAI-B for Breast
Multi-Reader Multi-Case, Retrospective Study to Evaluate Effectiveness of CadAI-B for Breast
The purpose of this study is to evaluate the effectiveness of lesion detection and diagnosis-aiding software (CadAI-B for Breast) during ultrasound (US) examination
Study Overview
Detailed Description
CadAI-B for Breast is a real-time artificial intelligence (AI) diagnosis system designed to assist healthcare professionals in lesion detection and differential diagnosis during breast US examinations. The primary objective of the study is to evaluate the effectiveness of CadAI-B in the assistance of detection and diagnosis of breast cancer by comparing the clinical performance of physicians before and after using CadAI-B in their ultrasound reading. The secondary objective of this study is to evaluate the sensitivity and specificity using CadAI-B for US examinations.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Seoul, South Korea, 03722
- Yonsei University Severance Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Mainly recruited from a tertiary hospital but no limitation of enrollment
Description
Inclusion Criteria:
- Women who underwent breast US examination
- Women with breast cancer (DCIS or invasive cancer) diagnosed via biopsy
- Women who had been followed for more than 2 years after initial US examination
Exclusion Criteria:
- women who had breast implants
- women who had US images containing artifacts affecting the review of images
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: RETROSPECTIVE
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Cancer group
confirmed as a breast cancer (ductal carcinoma in situ (DCIS) or invasive cancer) through the subsequent biopsy conducted within following 1 year of the ultrasound exam. |
CadAI-B for Breast is designed to assist healthcare professionals in lesion detection and differential diagnosis during breast US examinations. |
|
Benign group
Either confirmed as a benign through the subsequent biopsy conducted within following 1 year of the ultrasound exam or showing stability on more than 2 years of imaging follow-up after initial diagnosis |
CadAI-B for Breast is designed to assist healthcare professionals in lesion detection and differential diagnosis during breast US examinations. |
|
Normal group
Interpreted as Breast Imaging Reporting and Data System (BI-RADS) category 1 (Negative) with no cancers on the ultrasound exam |
CadAI-B for Breast is designed to assist healthcare professionals in lesion detection and differential diagnosis during breast US examinations. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Area Under the LROC Curve
Time Frame: 6 weeks
|
Area Under the Localization Receiver Operating Characteristic (LROC) Curve |
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Lesion detection sensitivity and specificity
Time Frame: 6 weeks
|
The mean sensitivity and specificity of 15 readers were calculated and compared between the aided and unaided sessions. |
6 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DP0001-SEV-CAB-II
- RS-2023-00227526 (Other Grant/Funding Number: Korea Ministry of Science and ICT)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.